|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2011-3-22
|
|
pubmed:abstractText |
Rationally designed therapies aim at the specific disruption of critical signaling pathways activated by malignant transformation or signals from the tumor microenvironment. Because mammalian target of rapamycin (mTOR) is an important signal integrator and a key translational regulator, we evaluated its potential involvement in T-cell acute lymphoblastic leukemia (T-ALL) and whether mTOR blockade synergizes with chemotherapeutic agents or other signaling antagonists to inhibit primary leukemia T cells.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/2-(4-morpholinyl)-8-phenyl-4H-1-benz...,
http://linkedlifedata.com/resource/pubmed/chemical/Antibiotics, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Chromones,
http://linkedlifedata.com/resource/pubmed/chemical/Dexamethasone,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/EIF4G1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Eukaryotic Initiation Factor-4G,
http://linkedlifedata.com/resource/pubmed/chemical/Janus Kinase 3,
http://linkedlifedata.com/resource/pubmed/chemical/MTOR protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Morpholines,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphatidylinositol 3-Kinase,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-akt,
http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines,
http://linkedlifedata.com/resource/pubmed/chemical/Sirolimus,
http://linkedlifedata.com/resource/pubmed/chemical/TOR Serine-Threonine Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/WHI P131,
http://linkedlifedata.com/resource/pubmed/chemical/temsirolimus
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1873-2399
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
39
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
457-472.e3
|
|
pubmed:meshHeading |
pubmed-meshheading:21277936-Antibiotics, Antineoplastic,
pubmed-meshheading:21277936-Cell Cycle,
pubmed-meshheading:21277936-Cell Line, Tumor,
pubmed-meshheading:21277936-Cell Proliferation,
pubmed-meshheading:21277936-Cell Survival,
pubmed-meshheading:21277936-Chromones,
pubmed-meshheading:21277936-Dexamethasone,
pubmed-meshheading:21277936-Doxorubicin,
pubmed-meshheading:21277936-Drug Synergism,
pubmed-meshheading:21277936-Enzyme Inhibitors,
pubmed-meshheading:21277936-Eukaryotic Initiation Factor-4G,
pubmed-meshheading:21277936-Humans,
pubmed-meshheading:21277936-Immunoblotting,
pubmed-meshheading:21277936-Immunohistochemistry,
pubmed-meshheading:21277936-Janus Kinase 3,
pubmed-meshheading:21277936-Microscopy, Fluorescence,
pubmed-meshheading:21277936-Morpholines,
pubmed-meshheading:21277936-Phosphatidylinositol 3-Kinase,
pubmed-meshheading:21277936-Phosphorylation,
pubmed-meshheading:21277936-Precursor T-Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:21277936-Proto-Oncogene Proteins c-akt,
pubmed-meshheading:21277936-Quinazolines,
pubmed-meshheading:21277936-Signal Transduction,
pubmed-meshheading:21277936-Sirolimus,
pubmed-meshheading:21277936-TOR Serine-Threonine Kinases
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.
|
|
pubmed:affiliation |
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass., USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
